meta:
  schema_version: '1.0'
  generated_by: Dawn (literature curation)
  last_updated: '2026-02-13'
  compatible_engine: cellswarm>=2.0
pathway_id: PD1_PDL1
pathway_name: PD-1/PD-L1 Immune Checkpoint
category: immune_checkpoint
kegg_id: hsa04514
components:
  receptors:
  - PDCD1
  ligands:
  - CD274
  - PDCD1LG2
  downstream:
  - SHP2
  - PI3K
  - AKT
  - RAS
  transcription_factors:
  - NFAT
  - AP1
  - NFKB
  key_genes:
  - PDCD1
  - CD274
  - PDCD1LG2
  - PTPN11
signal_fields_affected:
- PD_L1
- IFN_gamma
cell_type_effects:
  CD8_T:
    when_active: PD-1 engagement inhibits TCR signaling via SHP2, reducing proliferation,
      cytokine production, and cytotoxicity. Promotes exhaustion.
    behavioral_mapping:
      attack: -0.3
      proliferate: -0.2
      rest: 0.25
      migrate: 0.1
      apoptosis: 0.05
      signal: -0.1
    state_effects:
      exhaustion: 0.15
      activation: -0.2
      cytotoxicity: -0.25
  Tumor:
    when_active: PD-L1 expression enables immune evasion. High PD-L1 tumors resist
      T cell killing.
    behavioral_mapping:
      evade: 0.35
      proliferate: 0.05
    state_effects:
      immune_evasion: 0.3
  Treg:
    when_active: PD-1 signaling on Tregs can enhance suppressive function in TME.
    behavioral_mapping:
      suppress: 0.1
    state_effects:
      suppressive_activity: 0.1
  Macrophage:
    when_active: PD-1 on macrophages reduces phagocytic activity.
    behavioral_mapping:
      phagocytose: -0.15
      polarize: 0.1
    state_effects:
      phagocytic_activity: -0.15
  NK:
    when_active: PD-1 expression on NK cells impairs cytotoxicity.
    behavioral_mapping:
      attack: -0.2
    state_effects:
      cytotoxicity: -0.15
  B_cell:
    when_active: PD-1 on B cells modulates antibody responses.
    behavioral_mapping:
      signal: -0.1
    state_effects:
      antibody_secretion: -0.1
crosstalk:
- pathway: CTLA4_CD28
  type: synergistic_inhibition
  description: PD-1 and CTLA-4 inhibit T cells via distinct mechanisms; dual blockade
    is synergistic
- pathway: IFNG_JAK_STAT
  type: negative_feedback
  description: IFN-gamma upregulates PD-L1 expression, creating adaptive immune resistance
- pathway: TCR_signaling
  type: antagonistic
  description: PD-1 directly antagonizes proximal TCR signaling via SHP2
targeted_by:
- drug_id: pembrolizumab
  mechanism: Anti-PD-1 monoclonal antibody
- drug_id: nivolumab
  mechanism: Anti-PD-1 monoclonal antibody
- drug_id: atezolizumab
  mechanism: Anti-PD-L1 monoclonal antibody
- drug_id: durvalumab
  mechanism: Anti-PD-L1 monoclonal antibody
references:
- description: PD-1 blockade in cancer immunotherapy. Topalian et al. NEJM 2012
  pmid: '22658128'
  pmid_verified: true
- description: PD-L1 adaptive resistance mechanism. Ribas. Cancer Discov 2015
  pmid: '26272491'
  pmid_verified: true
additional_agents:
- drug_id: avelumab
  mechanism: Anti-PD-L1 monoclonal antibody
  in_drug_library: false
data_calibration:
  source: GSE176078 TNBC scRNA-seq (CellChat-lite)
  n_cells: 997
  communication_strength: 0.0187
  max_communication_strength: 0.0362
  n_active_pairs: 2
  top_interactions:
  - sender: Macrophage
    receiver: CD8_T
    ligand: PDCD1LG2
    receptor: PDCD1
    probability: 0.0362
  - sender: Tumor
    receiver: CD8_T
    ligand: CD274
    receptor: PDCD1
    probability: 0.0012
